• Publications
  • Influence
A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota
Omega-3 PUFA supplementation induces a reversible increase in several short-chain fatty acid-producing bacteria, independently of the method of administration, as well as a reversible increased abundance of several genera, including Bifidobacterium and Lactobacillus. Expand
Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass spectrometry.
The distribution of AQ4N and AQ4 in treated H460 human tumour xenografts has been examined by imaging matrix-assisted laser desorption/ionisation mass spectrometry and indicates that the cytotoxic metabolite AQ4 is confined to hypoxic regions of the tumour as intended. Expand
Comparative Preclinical Pharmacokinetic and Metabolic Studies of the Combretastatin Prodrugs Combretastatin A4 Phosphate and A1 Phosphate
Although in vitro studies suggest that variable rates of tumor-specific prodrug dephosphorylation may explain differences in pharmacokinetics profiles, the improved antitumor activity and altered pharmacokinetic profile of CA1 may be due to the formation of a more reactive metabolite. Expand
5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study
DMXAA is a novel vascular targeting agent and is well tolerated; dose-limiting toxicities in the form of urinary incontinence, visual disturbance, and anxiety were observed at the highest dose level. Expand
Separation methods for anthraquinone related anti-cancer drugs.
  • P. Loadman, C. Calabrese
  • Chemistry, Medicine
  • Journal of chromatography. B, Biomedical sciences…
  • 25 November 2001
Some of the separation techniques used for the analysis of anthracycline-related anti-cancer agents, including novel compounds such as AQ4N and C1311, both awaiting clinical trial are reviewed. Expand
Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma.
This study demonstrates that extensive necrosis occurred in a treated refractory murine colon adenocarcinoma but the damage was not accompanied by any measurable effect on tumour growth, and suggests that if an antivascular mechanism can be demonstrated in humans, combination chemotherapy should be rapidly assessed in a clinical setting. Expand
Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study
Intratumoral concentrations of AQ4 exceeded those required for activity in animal models and support the evaluation of AQ 4N as a novel tumor-targeting agent in future clinical studies. Expand
Effect of eicosapentaenoic acid on E-type prostaglandin synthesis and EP4 receptor signaling in human colorectal cancer cells.
It is concluded that EPA-FFA drives a COX-2-dependent "PGE (2)-to-PGE(3) switch" in human CRC cells and that PGE (3) acts as a partial agonist at the PGE(2) EP4 receptor. Expand
Anticolorectal cancer activity of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid
In the first 18 months after CRCLM resection, EPA-FFA-treated individuals obtained OS benefit compared with placebo, although early CRC recurrence rates were similar, and limited preoperative treatment may provide postoperative OS benefit. Expand
FGFR1-Induced Epithelial to Mesenchymal Transition through MAPK/PLCγ/COX-2-Mediated Mechanisms
It is demonstrated that FGFR1 activation in UC cells lines promotes EMT via coordinated activation of multiple signalling pathways and by promoting activation of prostaglandin synthesis. Expand